H.C. WAINWRIGHT & CO. 24TH ANNUAL GLOBAL INVESTMENT CONFERENCE


Associated tags: Lurasidone, Pfizer, Pharmaceutical industry, NMDA, Health, ECT, ASIB, FDA, Breakthrough therapy, Conference, SPA, Novartis, Depression, Lilly, Ketamine, Suicide, PTSD, Brain, Bipolar disorder

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 8, 2022
Lists of diseases, Novartis, Treatment, BTD, Electroconvulsive therapy, Bipolar disorder, Brain, PTSD, Suicide, Goal, Ketamine, Lilly, Depression, SPA, Lurasidone, Conference, Nasdaq, Breakthrough therapy, FDA, ASIB, ECT, Risk, Private Securities Litigation Reform Act, Health, NMDA, Pharmaceutical industry, Pfizer, Patient, Company

RADNOR, Pa., Sept. 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company's business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

Key Points: 
  • The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation & behavior (ASIB) remains electroconvulsive therapy (ECT).
  • Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect.
  • NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.